(Ivacaftor + tezacaftor) + ivacaftor is a Small Molecule owned by Vertex Pharmaceuticals, and is involved in 26 clinical trials, of which 23 were completed, and 3 are ongoing.

VX-661 and ivacaftor act as cystic fibrosis transmembrane conductance regulator (CFTR) corrector. Ivacaftor facilitates increased chloride transport by potentiating. CFTR potentiator helps the CFTR channels to open. CFTR channel activity is regulated by phosphorylation, ATP binding, and hydrolysis. It increases CFTR function by increasing the movement of CFTR to the cell surface.

The revenue for (Ivacaftor + tezacaftor) + ivacaftor is expected to reach a total of $1.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Ivacaftor + tezacaftor) + ivacaftor NPV Report.

(Ivacaftor + tezacaftor) + ivacaftor was originated by Cystic Fibrosis Foundation Therapeutics and Vertex Pharmaceuticals and is currently owned by Vertex Pharmaceuticals.

(Ivacaftor + tezacaftor) + ivacaftor Overview

Ivacaftor and tezacaftor (Symdeko, Symkevi) is a combination of tezacaftor and ivacaftor as fixed dose combination, along with ivacaftor as a kit. It is formulated as a kit co-packaged as a tezacaftor/ivacaftor fixed-dose combination film coated tablets and an ivacaftor film coated tablets, for oral route of administration. Symdeko is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene  that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence,and also for treatment of pediatric patients ages 6 years and older with cystic fibrosis who have certain genetic mutations.

Tezacaftor (VX-661) in combination with ivacaftor is under development for the treatment of cystic fibrosis (CF) (two copies of the F508del mutation or one F508del mutation and one residual function mutation) in children with 6-11 years.

Vertex Pharmaceuticals Overview

Vertex Pharmaceuticals (Vertex) is a biotechnology company that discovers, develops and commercializes transformative drugs for the treatment of serious and life-threatening diseases. The company’s product portfolio includes Trikafta, Symdeko/Symkevi, Orkambi (ivacaftor/lumacaftor), and Kalydeco (ivacaftor) for the treatment of cystic fibrosis. Through its research and development efforts, the company focuses on influenza, cancer, neurological diseases, and pain. It uses state-of-the-art technology platforms to discover new disease targets, compounds, delivery mechanisms, and treatment modalities. Vertex has R&D centers and commercial offices in North America, South America, Europe, and Australia. The company offers its products in the US, Europe, Australia, and Canada. Vertex is headquartered in Boston, Massachusetts, the US.

The company reported revenues of (US Dollars) US$7,574.4 million for the fiscal year ended December 2021 (FY2021), an increase of 22.1% over FY2020. In FY2021, the company’s operating margin was 36.7%, compared to an operating margin of 46% in FY2020. In FY2021, the company recorded a net margin of 30.9%, compared to a net margin of 43.7% in FY2020. The company reported revenues of US$2,334.3 million for the third quarter ended September 2022, an increase of 6.3% over the previous quarter.

Quick View – (Ivacaftor + tezacaftor) + ivacaftor

Report Segments
  • Innovator (NME)
Drug Name
  • (Ivacaftor + tezacaftor) + ivacaftor
Administration Pathway
  • Oral
Therapeutic Areas
  • Respiratory
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.